CURRENT
ISSUE
1531

Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.1

EFFECTIVENESS — The effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza illness depends on the match between the vaccine and circulating strains. Vaccine effectiveness is highest (40-60%) when the match is close, but even when the match is poor, vaccination has been shown to reduce the risk of hospitalization and death from influenza.2-4 For the 2016-2017 influenza season, the adjusted overall effectiveness of the seasonal influenza vaccine against influenza A and B viruses was 42%.5

COMPOSITION — All seasonal influenza vaccines available in the US contain the same two influenza A virus antigens. Trivalent vaccines contain only one influenza B virus...  Continue reading

More from Issue 1531
Previous Issue: 1530      September 25, 2017
Coming Soon
Drugs for Some Common Bacterial Infections in Adults
Tisagenlecleucel (Kymriah) for ALL
Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia
Search
Subscribe
Reader Testimonials
Watch the video!
Conversation
Follow us  facebook        Email Alerts
 Tweets
FROM
ISSUE
1531

The FDA has approved Mavyret (Abbvie) and Vosevi (Gilead), two new fixed-dose combinations of direct-acting antiviral (DAA) drugs, for treatment of chronic hepatitis C virus (HCV) infection caused by any of the six major HCV genotypes in patients without cirrhosis or with compensated cirrhosis. Both are approved for use in treatment-experienced patients. Mavyret is also approved for treatment-naive patients.

HCV GENOTYPES — HCV genotype 1 accounts for about 75% of HCV infections in the US, genotypes 2 and 3 account for about ... Continue reading